慢性丙型肝炎及抗病毒无干扰素治疗期间的免疫系统调节。
Modulation of the Immune System in Chronic Hepatitis C and During Antiviral Interferon-Free Therapy.
机构信息
Department of Immunology, Transplant Medicine and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
Department of Clinical Immunology, Medical University of Warsaw, Warsaw, Poland.
出版信息
Arch Immunol Ther Exp (Warsz). 2019 Apr;67(2):79-88. doi: 10.1007/s00005-018-0532-8. Epub 2018 Nov 15.
Abstract
The treatment of patients with chronic hepatitis C virus (HCV) infection has changed tremendously over the past 2 years, with an increasing variety of all-oral direct-acting antiviral (DAA) treatment regimens available for different HCV genotypes and distinct clinical settings. These treatments have significantly improved safety in patients with advanced liver disease compared with interferon (IFN)-based regimens. HCV modifies the human immune system to escape immunosurveillance via several mechanisms. One of the basic mechanisms of HCV is the ability to "switch" the immune response by reducing the activity of cells responsible for the elimination of virus-infected cells. IFN-free DAA treatment regimens provide a unique opportunity to assess the effect of HCV elimination on the immune system. Abrupt changes in the immune system can in some cases be responsible for two alarming processes: viral reactivation in patients with chronic hepatitis B and recurrence of hepatocellular carcinoma in patients with previous successful cancer treatment.
摘要
在过去的 2 年中，慢性丙型肝炎病毒（HCV）感染患者的治疗发生了巨大变化，越来越多的全口服直接作用抗病毒（DAA）治疗方案可用于不同的 HCV 基因型和不同的临床环境。与基于干扰素（IFN）的方案相比，这些治疗方案显著提高了晚期肝病患者的安全性。HCV 通过多种机制改变人体免疫系统以逃避免疫监视。HCV 的基本机制之一是通过降低负责清除病毒感染细胞的细胞的活性来“切换”免疫反应的能力。无干扰素 DAA 治疗方案为评估 HCV 消除对免疫系统的影响提供了独特的机会。免疫系统的突然变化在某些情况下可能是导致两种令人担忧的过程的原因：慢性乙型肝炎患者的病毒再激活和先前成功癌症治疗患者的肝细胞癌复发。
相似文献
1
Modulation of the Immune System in Chronic Hepatitis C and During Antiviral Interferon-Free Therapy.慢性丙型肝炎及抗病毒无干扰素治疗期间的免疫系统调节。
Arch Immunol Ther Exp (Warsz). 2019 Apr;67(2):79-88. doi: 10.1007/s00005-018-0532-8. Epub 2018 Nov 15.
2
Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy.直接抗病毒治疗后 HCC 复发的分子机制。
Int J Mol Sci. 2018 Dec 22;20(1):49. doi: 10.3390/ijms20010049.
3
Increased peripheral CD4 regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C.慢性丙型肝炎经直接作用抗病毒治疗后外周血 CD4 调节性 T 细胞持续增加。
J Hepatol. 2017 May;66(5):888-896. doi: 10.1016/j.jhep.2016.12.019. Epub 2016 Dec 29.
4
The Path to Cancer and Back: Immune Modulation During Hepatitis C Virus Infection, Progression to Fibrosis and Cancer, and Unexpected Roles of New Antivirals.从肝炎到肝癌：丙型肝炎病毒感染期间的免疫调节、纤维化和癌症进展，以及新型抗病毒药物的意外作用。
Transplantation. 2017 May;101(5):910-915. doi: 10.1097/TP.0000000000001623.
5
Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.比较直接抗病毒疗法与基于干扰素的丙型肝炎治疗方法之间乙肝病毒再激活的风险。
J Viral Hepat. 2017 Dec;24(12):1098-1106. doi: 10.1111/jvh.12737. Epub 2017 Jul 29.
6
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.接受无干扰素治疗的丙型肝炎相关 HCC 患者早期肿瘤复发率高。
J Hepatol. 2016 Oct;65(4):719-726. doi: 10.1016/j.jhep.2016.04.008. Epub 2016 Apr 13.
7
Immune Reconstitution After HCV Clearance With Direct Antiviral Agents: Potential Consequences for Patients With HCC?直接抗病毒药物清除 HCV 后的免疫重建：对 HCC 患者有何潜在影响？
Transplantation. 2017 May;101(5):904-909. doi: 10.1097/TP.0000000000001606.
8
Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection.干扰素刺激基因在丙型肝炎病毒感染固有免疫应答中的新作用
Cell Mol Immunol. 2016 Jan;13(1):11-35. doi: 10.1038/cmi.2014.127. Epub 2014 Dec 29.
9
Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.肝细胞癌会降低使用直接作用抗病毒药物成功治疗丙型肝炎病毒的几率。
J Hepatol. 2017 Jun;66(6):1173-1181. doi: 10.1016/j.jhep.2017.01.020. Epub 2017 Feb 2.
10
Impact of IFN-Free and IFN-Based Treatment on Blood Myeloid Dendritic Cell, Monocyte, Slan-DC, and Activated T Lymphocyte Dynamics during HCV Infection.无干扰素和基于干扰素治疗对 HCV 感染期间血液髓样树突状细胞、单核细胞、Slan-DC 和活化 T 淋巴细胞动力学的影响。
J Immunol Res. 2020 Mar 16;2020:2781350. doi: 10.1155/2020/2781350. eCollection 2020.
引用本文的文献
1
Metformin in Antiviral Therapy: Evidence and Perspectives.二甲双胍在抗病毒治疗中的应用：证据与展望
Viruses. 2024 Dec 18;16(12):1938. doi: 10.3390/v16121938.
2
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?直接作用抗病毒药物治疗慢性丙型肝炎感染与肝细胞癌的发生/复发：这仍然重要吗？
Viruses. 2024 Dec 10;16(12):1899. doi: 10.3390/v16121899.
3
Sustained Long-Term Decline in Anti-HCV Neutralizing Antibodies in HIV/HCV-Coinfected Patients Five Years after HCV Therapy: A Retrospective Study.丙型肝炎病毒（HCV）治疗五年后，HIV/HCV合并感染患者体内抗HCV中和抗体的持续长期下降：一项回顾性研究
Pharmaceuticals (Basel). 2024 Aug 30;17(9):1152. doi: 10.3390/ph17091152.
4
Cryptococcal Meningitis in an Immunocompetent Patient With Underlying Risk Factors.具有潜在危险因素的免疫功能正常患者的隐球菌性脑膜炎
Cureus. 2024 Jul 12;16(7):e64387. doi: 10.7759/cureus.64387. eCollection 2024 Jul.
5
Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients.基于血清白细胞介素-12 和白细胞介素 28B 基因单核苷酸多态性预测 HCV 阳性基因型 4 患者对索非布韦治疗的反应。
Medicine (Baltimore). 2023 Jul 14;102(28):e34125. doi: 10.1097/MD.0000000000034125.
6
Unusual Case of Non-HIV Patient With Multifocal Pyomyositis: Developed on Appropriate Antibiotic Therapy.非HIV患者多灶性脓性肌炎的罕见病例：在适当抗生素治疗后发病
J Med Cases. 2022 Aug;13(8):391-395. doi: 10.14740/jmc3967. Epub 2022 Aug 19.
7
Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis.新型聚乙二醇干扰素治疗慢性病毒性肝炎。
Viruses. 2022 May 25;14(6):1128. doi: 10.3390/v14061128.
8
Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening.通过全面的功能筛选鉴定 HCV E1E2 中的易损位点。
Cell Rep. 2022 May 24;39(8):110859. doi: 10.1016/j.celrep.2022.110859.
9
A 56-Year-Old Woman with Chronic Hepatitis C Liver Disease and Meningitis due to subsp. .一名56岁患有慢性丙型肝炎肝病且因亚种导致脑膜炎的女性。
Case Rep Crit Care. 2021 Oct 1;2021:7227054. doi: 10.1155/2021/7227054. eCollection 2021.
10
Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy.在人类免疫缺陷病毒（HIV）-丙型肝炎病毒（HCV）合并感染患者中，使用直接抗病毒药物治疗后丙型肝炎病毒（HCV）清除对接受抗逆转录病毒治疗时的全身免疫激活及HIV转录的影响
Open Forum Infect Dis. 2020 Apr 2;7(5):ofaa115. doi: 10.1093/ofid/ofaa115. eCollection 2020 May.
本文引用的文献
1
Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance.丙型肝炎病毒持续病毒学应答的实现降低了肝细胞癌肿瘤负荷：释放T细胞介导的免疫监视潜力。
J Hepatocell Carcinoma. 2018 May 31;5:55-59. doi: 10.2147/JHC.S152569. eCollection 2018.
2
The Janus Face of Follicular T Helper Cells in Chronic Viral Infections.慢性病毒感染中滤泡辅助性T细胞的双面性
Front Immunol. 2018 May 25;9:1162. doi: 10.3389/fimmu.2018.01162. eCollection 2018.
3
Recent advances in the discovery and development of TLR ligands as novel therapeutics for chronic HBV and HIV infections.TLR 配体作为慢性乙型肝炎和艾滋病病毒感染新型治疗药物的发现和研发的最新进展。
Expert Opin Drug Discov. 2018 Jul;13(7):661-670. doi: 10.1080/17460441.2018.1473372. Epub 2018 May 17.
4
Things fall apart with hepatocellular carcinoma and direct-acting antivirals.肝细胞癌和直接作用抗病毒药物会导致病情恶化。
Expert Opin Drug Saf. 2018 Feb;17(2):107-109. doi: 10.1080/14740338.2018.1404026. Epub 2017 Nov 14.
5
HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.直接作用抗病毒药物诱导的丙型肝炎病毒清除可降低肝细胞癌的风险。
J Hepatol. 2017 Sep 5. doi: 10.1016/j.jhep.2017.08.030.
6
Severe autoimmune hemolytic anemia during pegylated interferon plus ribavirin treatment for chronic hepatitis C: a case report.聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎期间发生的严重自身免疫性溶血性贫血：一例报告
Clin Case Rep. 2017 Jul 27;5(9):1490-1492. doi: 10.1002/ccr3.1098. eCollection 2017 Sep.
7
The occurrence of autoantibodies in patients with chronic HCV infection, including patients dialyzed and after kidney transplantation.慢性丙型肝炎病毒（HCV）感染患者，包括接受透析的患者和肾移植后的患者，体内自身抗体的出现情况。
Clin Exp Hepatol. 2016 Dec;2(4):161-166. doi: 10.5114/ceh.2016.63874. Epub 2016 Nov 28.
8
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.直接作用抗病毒 HCV 治疗后肝细胞癌风险：系统评价、荟萃分析和荟萃回归。
J Hepatol. 2017 Dec;67(6):1204-1212. doi: 10.1016/j.jhep.2017.07.025. Epub 2017 Aug 9.
9
Introducing treat-to-target strategies of autoimmune extrahepatic manifestations of chronic hepatitis C virus infection.介绍丙型肝炎病毒慢性感染自身免疫性肝外表现的治疗达标策略。
Expert Rev Clin Pharmacol. 2017 Oct;10(10):1085-1101. doi: 10.1080/17512433.2017.1357466. Epub 2017 Jul 27.
10
Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C.接受直接抗病毒药物治疗丙型肝炎的患者中乙肝再激活的风险。
World J Gastroenterol. 2017 Jun 28;23(24):4317-4323. doi: 10.3748/wjg.v23.i24.4317.
Zotero 插件